Rapport Therapeutics (RAPP) Payables (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Payables of $6.6 million for Q1 2026, up 206.73% year-over-year from $2.1 million in Q1 2025, and up 56.59% quarter-over-quarter from $4.2 million in Q4 2025.
Rapport Therapeutics (RAPP) Payables (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Payables for 4 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 206.73% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (up 206.73% YoY), while the FY2025 annual figure was $4.2 million, up 114.43% from the prior year.
- Payables advanced to $6.6 million in Q1 2026 per RAPP's latest filing, from $4.2 million in the prior quarter.
- Across five years, Payables topped out at $6.6 million in Q1 2026 and bottomed at $1.3 million in Q3 2024.
- Historically, Payables has averaged $3.0 million across 4 years, with a median of $2.5 million in 2023.
- Annual changes were most pronounced in 2024 — Payables decreased 21.9% — and 2026, when it surged 206.73%.
- Rapport Therapeutics' Payables stood at $2.5 million in 2023, then declined by 21.9% to $2.0 million in 2024, then soared by 114.43% to $4.2 million in 2025, then jumped by 56.59% to $6.6 million in 2026.
- Business Quant data shows RAPP's Payables at $6.6 million in Q1 2026, $4.2 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.80 Mn |
| Mar 31, 2026 | 6.56 Mn |
| Dec 31, 2025 | 4.19 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Dec 31, 2023 | 2.50 Mn |